Hybrid polypeptides having glucose lowering activity

Details Hybrid polypeptides having glucose lowering activity Hybrid polypeptides having glucose lowering activity

2005-08-17

2011-12-13

Chandra, Gyan (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S006800

Reexamination Certificate

active

08076288

ABSTRACT:
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

REFERENCES:
patent: 4397780 (1983-08-01), Orlowski et al.
patent: 4401593 (1983-08-01), Orlowski et al.
patent: 4414149 (1983-11-01), Orlowski et al.
patent: 4444981 (1984-04-01), Goudie
patent: 4495097 (1985-01-01), Orlowski et al.
patent: 4497731 (1985-02-01), Orlowski et al.
patent: 4537716 (1985-08-01), Orlowski et al.
patent: 4597900 (1986-07-01), Orlowski et al.
patent: 4604238 (1986-08-01), Orlowski et al.
patent: 4606856 (1986-08-01), Seyler et al.
patent: 4652627 (1987-03-01), Kempe et al.
patent: 4687839 (1987-08-01), Kempe
patent: 4697002 (1987-09-01), Kempe
patent: 5118666 (1992-06-01), Habener
patent: 5188666 (1993-02-01), Boccardo
patent: 5234906 (1993-08-01), Young et al.
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen et al.
patent: 5521283 (1996-05-01), DiMarchi et al.
patent: 5532336 (1996-07-01), DiMarchi et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5604203 (1997-02-01), Balasubramaniam
patent: 5686511 (1997-11-01), Bobo
patent: 5739106 (1998-04-01), Rink et al.
patent: 5789379 (1998-08-01), Drucker
patent: 5824778 (1998-10-01), Ishikawa et al.
patent: 5824784 (1998-10-01), Kinstler et al.
patent: 5998367 (1999-12-01), Gaeta et al.
patent: 6184201 (2001-02-01), Drucker et al.
patent: 6506724 (2003-01-01), Hiles et al.
patent: 6528486 (2003-03-01), Larsen et al.
patent: 6558952 (2003-05-01), Parikh et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6747006 (2004-06-01), Efendic
patent: 2002/0141985 (2002-10-01), Pittner et al.
patent: 2003/0026812 (2003-02-01), Duft et al.
patent: 2004/0053370 (2004-03-01), Glaesner et al.
patent: 2004/0209803 (2004-10-01), Baron et al.
patent: 2004/0228846 (2004-11-01), Pang et al.
patent: 2006/0135747 (2006-06-01), Levy et al.
patent: 004791 (2004-08-01), None
patent: 1421950 (2004-05-01), None
patent: WO 91/08220 (1991-06-01), None
patent: WO9111457 (1991-08-01), None
patent: WO9519785 (1995-07-01), None
patent: WO9605309 (1996-02-01), None
patent: WO9622308 (1996-07-01), None
patent: WO 9631526 (1996-10-01), None
patent: WO9640196 (1996-12-01), None
patent: WO9702004 (1997-01-01), None
patent: WO9715322 (1997-05-01), None
patent: WO9727286 (1997-07-01), None
patent: WO9731621 (1997-09-01), None
patent: WO9805351 (1998-02-01), None
patent: WO9812224 (1998-03-01), None
patent: WO9818486 (1998-05-01), None
patent: WO98/28427 (1998-07-01), None
patent: WO9830231 (1998-07-01), None
patent: WO9836763 (1998-08-01), None
patent: WO9848831 (1998-11-01), None
patent: WO9855139 (1998-12-01), None
patent: WO9907404 (1999-02-01), None
patent: WO9925727 (1999-05-01), None
patent: WO 9925728 (1999-05-01), None
patent: WO00/73331 (2000-12-01), None
patent: WO 01/04156 (2001-01-01), None
patent: WO01/44284 (2001-06-01), None
patent: WO01/51078 (2001-07-01), None
patent: WO03/011892 (2003-02-01), None
patent: WO 03022304 (2003-03-01), None
patent: WO 03026591 (2003-04-01), None
patent: WO03/059934 (2003-07-01), None
patent: WO 03/059934 (2003-07-01), None
patent: WO 03057235 (2003-07-01), None
patent: WO2004037195 (2004-05-01), None
patent: WO2004039832 (2004-05-01), None
patent: WO2004/056313 (2004-07-01), None
patent: WO2004/103390 (2004-12-01), None
patent: WO 2005/000222 (2005-01-01), None
patent: WO2005/077072 (2005-08-01), None
patent: WO 2005/077094 (2005-08-01), None
patent: WO2005077072 (2005-08-01), None
patent: WO 2006/066024 (2006-06-01), None
patent: WO 2006/083254 (2006-08-01), None
patent: WO 2006/086769 (2006-08-01), None
patent: WO 2007/055728 (2007-05-01), None
Bork, A. Genome Res. 10:398-400, 2000.
Skolnick et al., 18(1):34-39, 2000.
Doerks et al., Trends in Genetics 14(6):248-250 1998.
Smith et al., Nature Biotech. 15:1222-1223, 1997.
Brenner, S.E., Trends in Genetics. 15(4):132-133, 1999.
Bork et al., Trends in Genetics. 12(10):425-427, 1996.
Wells, J.A. Biochemistry. 29(37):8509-8517, 1990.
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 492-495, 1994.
Reda et al., Obes. Res. 10: 1087-1091, 2002.
Szayna et al., Endocr. 141: 1936-1941, 2000.
Bhavsar et al., Phys. Behavior, 64: 557-561, 1998.
Baron, Alain et al., “Novel Peptides Under Development . . . ” current Drug Targets Immune Endocrine and Metabolic Disorders, vol. 2 No. 1 Apr. 2002.
U.S. Appl. No. 08/669,791.
Andreu, David, et al “Shortened Cecropin A—Melittin Hybrids”, FEBS (1992) 190-194, 296 (2).
Aponte, Gregory W., et al “Meal-Induced Peptide Tyrosine Tyrosine Inhibition of Pancreatic Secretion in the Rat”, FASEB J (1989) 1949-1955, 3.
Becker, K. L., et al “Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation . . . ”, JCEM (2004)1512-1525, 89 (4).
Bhavsar, Sunil, et al “Synergy Between Amylin and Cholecystokinin for Inhibition of Food Intake in Mice”, Physiol. & Behavior (1998) 557-561, 64.
Campfield, L. Arthur, et al “Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks”, Science (1995) 546-549, 269.
Cooper, G. J. S., et al “Amylin and the Amylin Gene: Structure, Function and Relationship to Islet Amyloid and to Diabetes Mellitus”, Biochim Biophys Acta (1989) 247-258, 1014.
Cooper, G. J. S., et al “Purification and Characterization of a Peptide from Amyloid-Rich Pancreases of Type 2 Diabetic Patients”, Proc. Natl. Acad. Sci. (1987) 8628-8632, 84.
Cox, James E., “Inhibitory Effects of Cholecystokinin Develop Through Interaction With Duodenal Signals”, Behav Brain Res (1990) 35-44, 38.
Crawley, Jacqueline N., et al “Biological Actions of Cholecystokinin”, Peptides (1994) 731-755, 15 (4).
Dasgupta, P., et al “Antiproliferative and GH-Inhibitory Activity of Chimeric Peptides Consisting of GHRP-6 and Somatostatin”, Biochem Biophys Res Commun (1999) 379-384, 259.
Dulawa, Stephanie C., et al “Cholecystokinin and Estradiol Synergistically Potentiate Satiety in Rats” Peptides (1994) 913-918, 15(5).
Eberlein, Gert A., et al “A New Molecular Form of PYY: Structural Characterization of Human PYY(3-36) and PYY (1-36)” Peptides (1989) 797-803, 10.
Farquhar, Michelle, et al “Novel Mastoparan Analogs Induce Differential Secretion from Mast Cells”, Chem Biol (2002) 63-70, 9.
Goke, R., et al “Glucagon-Like Peptide-1 (7-36) Amide is a New Incretin/Enterogastrone Candidate” J Biol Chem (1991) 135-144, 21.
Goke, R., et al “Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist . . . ”, J Biol Chem (1993) 19650-19655, 268(26).
Grandt, D., et al “Two Molecular Forms of Peptide YY (PYY) are Abundant in Human Blood: Characterization . . . ”, Regulatory Peptides (1994) 151-159, 51.
Halaas, Jeffrey L., et al “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene”, Science (1995) Effects of the Plasma Protein 543-546, 269.
Hinson, Joy P., et al “Adrenomedullin, a Multifunctional Regulatory Peptide”, Endocrine Reviews (2000) 138-167, 21(2).
Hinton, Veronica, et al “Combined Injection Potentiates the Satiety Effects of Pancreatic Glucagon, Cholecystokinin, and Bombesin”, Brain Res Bull (1986) 615-619, 17.
Hojo, Keiko, et al “Amino Acids and Peptides. Part 39:A Bivalent Poly(ethyleneglycol) Hybrid Containing . . . &#x

Affiliated with

Also associated with

Rating

Hybrid polypeptides having glucose lowering activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybrid polypeptides having glucose lowering activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid polypeptides having glucose lowering activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4307544